



Xencor Collaboration Agreement with Johnson & Johnson

Client News

October 4, 2021

Gunderson Dettmer represented client Xencor, a clinical-stage biopharmaceutical company, in its \$100 million collaboration agreement with Johnson & Johnson and Johnson & Johnson's related \$25 million equity investment in Xencor. The collaboration, which is worth up to \$1.2 billion in milestones, provides Johnson & Johnson with global rights to Xencor's CD20xCD3 bispecific antibody, plamotamab, and provides for further development of plamotamab as well as research and development of CD28 bispecific antibody candidates against B-cell targets.

In the [announcement of the agreement](#), President and CEO of Xencor Bassil Dahiyat said, "We are delighted to collaborate with Janssen's leading scientists to expand the scope of the plamotamab program, particularly as we explore opportunities to combine with novel B-cell targeted CD28 bispecific antibodies that can potentially selectively enhance T-cell cytotoxic activity. This collaboration complements our plans to initiate combination clinical trials of plamotamab with tafasitamab and lenalidomide, and it expands our strategy to develop multiple highly active chemotherapy-free regimens for B-cell cancers."

The Gunderson deal team was led by Brendan McCarthy and included Kirt Shuldberg, Aliya Sanders, and Jordan Murray.

Companies:

[Xencor](#)

[Johnson & Johnson](#)

[Related People](#)

Brendan C. McCarthy
PARTNER
P +1 858 436 8013

Kirt W Shuldberg
PARTNER
P +1 858 436 8060

Aliya J. Sanders
PARTNER
P +1 212 430 3172

Jordan F. Murray
ASSOCIATE
P +1 858 436 8047

Related Services

Strategic Transactions & Licensing

Featured Insights

PUBLIC VENTURES

Trump Executive Order Targets Proxy Advisors Over DEI and ESG Influence

EVENTS

Webinar: Paradigm Shift? Mandatory Securities Arbitration and the Impact of the SEC's Recent Policy Statement for Companies and Investors

FIRM NEWS

Amidst Strong Year, Gunderson Dettmer Elects Nine New Partners

EVENTS

Webinar: AI in the Workplace: Legal Challenges and Best Practices

FIRM NEWS

2025 CVCA Annual General Meeting & Private/Venture Capital Summit in Beijing

CLIENT NEWS

Gunderson Dettmer Represented Hims & Hers in Acquisition of Livewell

CLIENT NEWS

Replicate Bioscience Announces Collaborative Agreement with Instituto Butantan

CLIENT NEWS

Gunderson Client Neptune to Be Acquired by OpenAI

CLIENT NEWS

Hims & Hers Announces Definitive Agreement to Acquire YourBio Health

CLIENT NEWS

LotusFlare Announces Equity Investment from Ericsson

PUBLIC VENTURES

SEC Chair Charts Disclosure Overhaul to Revive IPOs: Materiality and Scale Over 'Regulatory Creep'

CLIENT NEWS

Vambe Raises \$14M Series A Led by Monashees